Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 224

1.

[Optimal duration of dual antiplatelet therapy after coronary stent placement or acute coronary syndrome. Is customisation possible?]

Georges JL, Cherif G, Ajlani B.

Ann Cardiol Angeiol (Paris). 2019 Aug 27. pii: S0003-3928(19)30055-1. doi: 10.1016/j.ancard.2019.07.011. [Epub ahead of print] French.

PMID:
31471043
2.

Final results of the Randomised Evaluation of short-term DUal antiplatelet therapy in patients with acute Coronary syndromE treated with a new generation stent (REDUCE) trial.

De Luca G, Damen SA, Camaro C, Benit E, Verdoia M, Rasoul S, Liew HB, Polad J, Ahmad WA, Zambahari R, Postma S, Kedhi E, Suryapranata H; Collaborators.

EuroIntervention. 2019 Aug 20. pii: EIJ-D-19-00539. doi: 10.4244/EIJ-D-19-00539. [Epub ahead of print]

3.

Optimal Duration of Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: An Umbrella Review.

Elliott J, Kelly SE, Bai Z, Liu W, Skidmore B, Boucher M, So DYF, Wells GA.

Can J Cardiol. 2019 Aug;35(8):1039-1046. doi: 10.1016/j.cjca.2019.01.021. Epub 2019 Feb 6. Review.

PMID:
31376905
4.

Persistence with dual antiplatelet therapy after percutaneous coronary intervention for ST-segment elevation acute coronary syndrome: a population-based cohort study in Catalonia (Spain).

Ribera A, Ferreira-Gonzalez I, Marsal JR, Oristrell G, Faixedas MT, Rosas A, Tizón-Marcos H, Rojas S, Labata C, Cardenas M, Homs S, Tomas-Querol C, Garcia-Picart J, Gomez-Hospital JA, Pijoan JI, Masotti M, Mauri J, Garcia Dorado D; VESA Study and Codi IAM Investigators.

BMJ Open. 2019 Jul 23;9(7):e028114. doi: 10.1136/bmjopen-2018-028114.

5.

Impact of platelet turnover on long-term adverse cardiovascular outcomes in patients undergoing percutaneous coronary intervention.

Tscharre M, Farhan S, Bruno V, Rohla M, Egger F, Weiss TW, Hübl W, Willheim M, Wojta J, Geppert A, Huber K, Freynhofer MK.

Eur J Clin Invest. 2019 Sep;49(9):e13157. doi: 10.1111/eci.13157. Epub 2019 Aug 19.

PMID:
31318979
6.

Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis.

Yin SH, Xu P, Wang B, Lu Y, Wu QY, Zhou ML, Wu JR, Cai JJ, Sun X, Yuan H.

BMJ. 2019 Jun 28;365:l2222. doi: 10.1136/bmj.l2222.

8.

Role of Gender in Dual Antiplatelet Therapy After Acute Coronary Syndrome.

Mallidi J, Lata K.

Curr Atheroscler Rep. 2019 Jun 22;21(9):34. doi: 10.1007/s11883-019-0795-5. Review.

PMID:
31230141
9.

Dual antiplatelet therapy following percutaneous coronary intervention: protocol for a systematic review.

Elliott J, Kelly SE, Bai Z, Skidmore B, Boucher M, So DYF, Wells GA.

BMJ Open. 2019 Jun 16;9(6):e022271. doi: 10.1136/bmjopen-2018-022271.

10.

[Is it necessary to prescribe oral anticoagulant therapy for paroxysmal atrial fibrillation during acute coronary syndrome, and for how long?]

Visconti LO, Ferlini M, Rordorf R, Savastano S.

G Ital Cardiol (Rome). 2019 Jun;20(6):361-366. doi: 10.1714/3165.31469. Italian.

PMID:
31184322
11.

Optimal duration of dual antiplatelet therapy post percutaneous coronary intervention in acute coronary syndrome.

Deharo P, Cuisset T.

Trends Cardiovasc Med. 2019 May 31. pii: S1050-1738(19)30073-8. doi: 10.1016/j.tcm.2019.05.008. [Epub ahead of print] Review.

12.

Improving adherence to Ticagrelor in patients after acute coronary syndrome: Results from the PROGRESS trial.

Crisci M, Gragnano F, Di Maio M, Diana V, Moscarella E, Pariggiano I, Di Maio D, Concilio C, Taglialatela V, Fimiani F, Cesaro A, Cirillo PL, Calabrò P.

Curr Vasc Pharmacol. 2019 May 24. doi: 10.2174/1570161117666190524123225. [Epub ahead of print]

PMID:
31124422
13.

Duration of Clopidogrel-Based Dual Antiplatelet Therapy and Clinical Outcomes in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention - A Real-World Observation in Taiwan From 2012 to 2015.

Li YH, Chiu YW, Cheng JJ, Hsieh IC, Lo PH, Lei MH, Ueng KC, Chiang FT, Sung SH, Kuo JY, Chen CP, Lai WT, Lee WL, Chen JH; Taiwan ACS STENT Registry Investigators.

Circ J. 2019 May 24;83(6):1317-1323. doi: 10.1253/circj.CJ-18-1283. Epub 2019 Apr 27.

14.

Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry.

De Filippo O, Cortese M, D Ascenzo F, Raposeiras-Roubin S, Abu-Assi E, Kinnaird T, Ariza-Solé A, Manzano-Fernández S, Templin C, Velicki L, Xanthopoulou I, Cerrato E, Rognoni A, Boccuzzi G, Montefusco A, Montabone A, Taha S, Durante A, Gili S, Magnani G, Autelli M, Grosso A, Blanco PF, Garay A, Quadri G, Varbella F, Queija BC, Paz RC, Fernández MC, Pousa IM, Gallo D, Morbiducci U, Dominguez-Rodriguez A, Valdés M, Cequier A, Alexopoulos D, Iñiguez-Romo A, Rinaldi M.

Am J Cardiovasc Drugs. 2019 Aug;19(4):381-391. doi: 10.1007/s40256-019-00339-3. Erratum in: Am J Cardiovasc Drugs. 2019 May 20;:.

PMID:
31030413
15.

Coronary Artery Ectasia: An Insight into Intraprocedural and Postprocedural Management Strategies.

Waqas M, Bizzocchi LL, Menegus MA, Faillace RT.

Cureus. 2019 Jan 21;11(1):e3928. doi: 10.7759/cureus.3928.

16.

Dual Antiplatelet Therapy: How Long Is Long Enough?

Flannery L, Liu R, Elmariah S.

Curr Treat Options Cardiovasc Med. 2019 Mar 30;21(4):17. doi: 10.1007/s11936-019-0721-8. Review.

PMID:
30929096
17.

Bleeding risk assessment in elderly patients with acute coronary syndrome.

Riobóo-Lestón L, Raposeiras-Roubin S, Abu-Assi E, Iñiguez-Romo A.

J Geriatr Cardiol. 2019 Feb;16(2):145-150. doi: 10.11909/j.issn.1671-5411.2019.02.002. Review.

18.

Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European Heart Rhythm Association survey.

Lane DA, Dagres N, Dan GA, García Seara J, Iliodromitis K, Lenarczyk R, Lip GYH, Mansourati J, Marín F, Scherr D, Potpara TS.

Europace. 2019 Jul 1;21(7):1116-1125. doi: 10.1093/europace/euz033.

PMID:
30874724
19.

Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical Presentation.

Palmerini T, Bruno AG, Gilard M, Morice MC, Valgimigli M, Montalescot G, Collet JP, Della Riva D, Bacchi-Reggiani ML, Steg PG, Diallo A, Vicaut E, Helft G, Nakamura M, Généreux P, Vahl TP, Stone GW.

Circ Cardiovasc Interv. 2019 Mar;12(3):e007541. doi: 10.1161/CIRCINTERVENTIONS.118.007541.

PMID:
30871353
20.

Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.

D'Ascenzo F, Bertaina M, Fioravanti F, Bongiovanni F, Raposeiras-Roubin S, Abu-Assi E, Kinnaird T, Ariza-Solé A, Manzano-Fernández S, Templin C, Velicki L, Xanthopoulou I, Cerrato E, Rognoni A, Boccuzzi G, Omedè P, Montabone A, Taha S, Durante A, Gili S, Magnani G, Autelli M, Grosso A, Blanco PF, Garay A, Quadri G, Varbella F, Queija BC, Paz RC, Fernández MC, Pousa IM, Gallo D, Morbiducci U, Dominguez-Rodriguez A, Valdés M, Cequier A, Alexopoulos D, Iñiguez-Romo A, Gaita F, Rinaldi M, Lüscher TF.

Eur J Prev Cardiol. 2019 Mar 12:2047487319836327. doi: 10.1177/2047487319836327. [Epub ahead of print]

PMID:
30862233

Supplemental Content

Loading ...
Support Center